(0.04%) 5 519.00 points
(0.13%) 39 894 points
(0.08%) 19 768 points
(-0.09%) $81.56
(0.43%) $2.82
(-0.23%) $2 338.90
(0.20%) $29.59
(0.56%) $1 007.40
(0.09%) $0.932
(-0.11%) $10.52
(0.02%) $0.788
(-0.85%) $87.25
2.97% $ 4.50
Live Chart Being Loaded With Signals
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens...
Stats | |
---|---|
Dzisiejszy wolumen | 1.53M |
Średni wolumen | 2.53M |
Kapitalizacja rynkowa | 281.85M |
EPS | $-0.840 ( Q1 | 2024-05-09 ) |
Następna data zysków | ( $-0.560 ) 2024-08-07 |
Last Dividend | $0 ( N/A ) |
Next Dividend | $0 ( N/A ) |
P/E |
-11.84 (Sector) 42.63 (Industry) 24.32 |
ATR14 | $0.0140 (0.31%) |
Date | Person | Action | Amount | type |
---|---|---|---|---|
2024-05-21 | Siegel Jay Philip | Buy | 16 500 | Stock Option (right to buy) |
2024-05-21 | Siegel Jay Philip | Buy | 6 500 | Restricted Stock Unit |
2024-05-21 | Chhabra Meenu | Buy | 17 077 | Stock Option (right to buy) |
2024-05-21 | Chhabra Meenu | Buy | 16 500 | Stock Option (right to buy) |
2024-05-21 | Chhabra Meenu | Buy | 6 500 | Restricted Stock Unit |
INSIDER POWER |
---|
40.12 |
Last 100 transactions |
Buy: 1 316 271 | Sell: 560 626 |
Wolumen Korelacja
MacroGenics Inc Korelacja
10 Najbardziej pozytywne korelacje | |
---|---|
FTNT | 0.816 |
10 Najbardziej negatywne korelacje |
---|
Did You Know?
Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).
Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.
MacroGenics Inc Korelacja - Waluta/Towar
MacroGenics Inc Finanse
Annual | 2023 |
Przychody: | $58.75M |
Zysk brutto: | $40.88M (69.59 %) |
EPS: | $-0.150 |
FY | 2023 |
Przychody: | $58.75M |
Zysk brutto: | $40.88M (69.59 %) |
EPS: | $-0.150 |
FY | 2022 |
Przychody: | $151.94M |
Zysk brutto: | $144.56M (95.14 %) |
EPS: | $-1.950 |
FY | 2021 |
Przychody: | $75.64M |
Zysk brutto: | $72.99M (96.50 %) |
EPS: | $-3.30 |
Financial Reports:
No articles found.
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
Contract Name | Last Trade Date (EDT) | Strike | Last Price | Bid | Ask | Change | % Change | Volume | Open Interest | Implied Volatility | Strike Date |
---|---|---|---|---|---|---|---|---|---|---|---|
No data available |
MacroGenics Inc
MacroGenics, Inc., a biopharmaceutical company, develops and commercializes antibody-based therapeutics to treat cancer in the United States. Its approved product is MARGENZA (margetuximab-cmkb), a human epidermal growth factor receptor 2 (HER2) receptor antagonist indicated, in combination with chemotherapy, for the treatment of adult patients with metastatic HER2-positive breast cancer who have received two or more prior anti-HER2 regimens. The company's pipeline of immuno-oncology product candidates includes MGC018, an antibody drug conjugate (ADC), which targets solid tumors expressing B7-H3; Enoblituzumab, a monoclonal antibody that targets B7-H3; and MGD024, an investigational bispecific CD123 × CD3 DART molecule to minimize cytokine-release syndrome for patients with hematologic malignancies. It also develops Lorigerlimab, a monoclonal antibody that targets the immune checkpoints PD-1 and cytotoxic T-lymphocyte-associated protein 4; Tebotelimab, an investigational tetravalent DART molecule for PD-1 and lymphocyte-activation gene 3; Retifanlimab, an investigational monoclonal antibody targeting metastatic squamous cell carcinoma of the anal canal and metastatic non-small cell lung cancer; and IMGC936, an ADC that targets ADAM9, a cell surface protein over-expressed in various solid tumor types. Further, the company develops MGD014 and MGD020, a DART molecule to target the envelope protein of human immunodeficiency virus infected cells and CD3 on T cells; Teplizumab for the treatment of type 1 diabetes; and PRV-3279, a CD32B × CD79B DART molecule for the treatment of autoimmune indications. It has collaborations with Incyte Corporation; Zai Lab Limited; I-Mab Biopharma; and Janssen Biotech, Inc. The company was incorporated in 2000 and is headquartered in Rockville, Maryland.
O Sygnały na żywo
Prezentowane na tej stronie sygnały na żywo pomagają określić, kiedy KUPIĆ lub SPRZEDAĆ BRAK DANYCH. Sygnały mogą mieć opóźnienie wynoszące nawet 1 minutę; jak wszystkie sygnały rynkowe, istnieje ryzyko błędu lub pomyłki.
Sygnały transakcyjne na żywo nie są ostateczne i getagraph.com nie ponosi odpowiedzialności za żadne działania podjęte na podstawie tych sygnałów, jak opisano w Warunkach Użytkowania. Sygnały opierają się na szerokim zakresie wskaźników analizy technicznej